<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755156</url>
  </required_header>
  <id_info>
    <org_study_id>3102-024</org_study_id>
    <secondary_id>2012-003670-11</secondary_id>
    <nct_id>NCT01755156</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of omarigliptin compared to
      placebo in participants with inadequate glycemic control on metformin monotherapy. The
      primary hypothesis is that after 24 weeks, the addition of treatment with omarigliptin
      provides greater reduction in hemoglobin A1c (A1C) than placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants received blinded omarigliptin or matching placebo to omarigliptin for 104 weeks.
      During the first 24 weeks (Phase A) they did not receive any other blinded study medication.
      In Phase B (subsequent 80 weeks), participants who did not initiate glycemic rescue in Phase
      A received additional blinded study medication: participants in the omarigliptin group
      received placebo to glimepiride and participants in the placebo group received glimepiride.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2013</start_date>
  <completion_date type="Actual">March 16, 2016</completion_date>
  <primary_completion_date type="Actual">March 16, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>A1C is measured as a percent. Change from baseline in A1C at Week 24 was analyzed using a constrained longitudinal data analysis (cLDA) method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Adverse Event (Phase A+B)</measure>
    <time_frame>Up to 107 weeks</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Presented data exclude data after glycemic rescue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A+B)</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Presented data exclude data after glycemic rescue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B)</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>The following laboratory parameters were included: blood chemistry, hematology, electrocardiograms, lipids, body weight, and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24 (Phase A)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in 2-hour PMG at Week 24 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in FPG at Week 24 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 104 (Phase A+B)</measure>
    <time_frame>Baseline and Week 104</time_frame>
    <description>A1C is measured as a percent. Change from baseline in A1C at Week 104 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 104 (Phase A+B)</measure>
    <time_frame>Baseline and Week 104</time_frame>
    <description>Change from baseline in FPG at Week 104 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Attaining A1C Glycemic Goals of &lt;7.0% After 24 Weeks of Treatment (Phase A)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of participants attaining A1C glycemic goals of &lt;7.0% (53 mmol/mol) after 24 weeks of treatment estimated using standard multiple imputation techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Attaining A1C Glycemic Goals of &lt;6.5% After 24 Weeks of Treatment (Phase A)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of participants attaining A1C glycemic goals of &lt;6.5% (48 mmol/mol) after 24 weeks of treatment estimated using standard multiple imputation techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Attaining A1C Glycemic Goals of &lt;7% After 104 Weeks of Treatment (Phase A+B)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Percentage of participants attaining A1C glycemic goals of &lt;7.0% (53 mmol/mol) after 104 weeks of treatment estimated using standard multiple imputation techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Attaining A1C Glycemic Goals of &lt;6.5% After 104 Weeks of Treatment (Phase A+B)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Percentage of participants attaining A1C glycemic goals of &lt;6.5% (48 mmol/mol) after 104 weeks of treatment estimated using standard multiple imputation techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PMG Total Area Under the Plasma Concentration Time Curve (AUC) at Week 24 (Phase A)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in PMG total AUC at Week 24 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment. Plasma glucose levels were measured before the meal (0 minutes), and at 60 and 120 minutes after the meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at Week 24 (Phase A)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in fasting insulin at Week 24 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at Week 104 (Phase A+B)</measure>
    <time_frame>Baseline and Week 104</time_frame>
    <description>Change from baseline in fasting insulin at Week 104 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 24 Weeks (Phase A)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Participants who did not meet progressively stricter glycemic criteria in Phase A had rescue initiated with open-label glimepiride.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 104 Weeks (Phase A+B)</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Participants who did not meet progressively stricter glycemic criteria in Phase A had rescue initiated with open-label glimepiride. If during Phase B participants on open-label glimepiride or blinded glimepiride/glimepiride matching placebo needed rescue after maximum up-titration, then insulin glargine was initiated and the dose of open-label glimepiride or blinded glimepiride/glimepiride-matching placebo was discontinued.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 24 (Phase A)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Data presented are a cumulative incidence of participants with glycemic rescue by Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B)</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Data presented are a cumulative incidence of participants with glycemic rescue by Week 104.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Omarigliptin (Phase A) → Omarigliptin (Phase B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omarigliptin</intervention_name>
    <description>Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)</description>
    <arm_group_label>Omarigliptin (Phase A) → Omarigliptin (Phase B)</arm_group_label>
    <other_name>MK-3102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo to omarigliptin</intervention_name>
    <description>Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)</description>
    <arm_group_label>Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.</description>
    <arm_group_label>Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)</arm_group_label>
    <other_name>Amaryl®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo to glimepiride</intervention_name>
    <description>Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.</description>
    <arm_group_label>Omarigliptin (Phase A) → Omarigliptin (Phase B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.</description>
    <arm_group_label>Omarigliptin (Phase A) → Omarigliptin (Phase B)</arm_group_label>
    <arm_group_label>Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants continue stable pre-study dose of metformin tablet(s) administered orally (&gt;= 1500 mg daily) throughout the study.</description>
    <arm_group_label>Omarigliptin (Phase A) → Omarigliptin (Phase B)</arm_group_label>
    <arm_group_label>Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)</arm_group_label>
    <other_name>Fortamet®</other_name>
    <other_name>Glucophage®</other_name>
    <other_name>Glucophage® XR</other_name>
    <other_name>Glumetza®</other_name>
    <other_name>Riomet®</other_name>
    <other_name>Metgluco®</other_name>
    <other_name>Glycoran®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has type 2 diabetes mellitus

          -  Currently on a stable dose of metformin monotherapy (&gt;=1500 mg per day) for at least
             12 weeks prior to study participation

          -  Male, or female who is not of reproductive potential or if of reproductive potential
             agrees to abstain from heterosexual activity or use (or have their partner use)
             acceptable contraception to prevent pregnancy during the study and for 21 days after
             the last dose of study drug

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or a history of ketoacidosis

          -  Has been treated with any antihyperglycemic agent (AHA) other than the
             protocol-required metformin within 12 weeks prior to study participation or with
             omarigliptin at any time prior to signing informed consent

          -  History of hypersensitivity to a dipeptidyl peptidase IV (DPP-4) inhibitor

          -  History of intolerance, hypersensitivity, or any other contraindication to metformin,
             glimepiride, or insulin glargine

          -  Is on a weight loss program and is not in the maintenance phase or has been on a
             weight loss medication in the past 6 months or has undergone bariatric surgery within
             12 months prior to study participation

          -  Has undergone a surgical procedure within 4 weeks of study participation or has
             planned major surgery during the study

          -  Is on or likely to require treatment for &gt;=2 consecutive weeks or repeated courses of
             corticosteroids (inhaled, nasal and topical corticosteroids are permitted)

          -  Currently being treated for hyperthyroidism or is on thyroid hormone replacement
             therapy and has not been on a stable dose for at least 6 weeks

          -  Is expecting to undergo hormonal therapy in preparation to donate eggs during the
             period of the trial, including 21 days after the last dose of blinded study medication

          -  History of active liver disease (other than non-alcoholic steatosis) including chronic
             active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease

          -  Human immunodeficiency virus (HIV)

          -  New or worsening signs or symptoms of coronary heart disease or congestive heart
             failure within the past 3 months, or myocardial infarction, unstable angina, coronary
             artery bypass grafting, percutaneous transluminal coronary angioplasty, stroke, or
             transient ischemic attacks in the past 3 months

          -  Poorly controlled hypertension

          -  History of malignancy &lt;=5 years prior to study participation, except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer

          -  Hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic
             syndromes, thrombocytopenia)

          -  Positive urine pregnancy test

          -  Pregnant or breastfeeding, or is expecting to conceive during the study including 21
             days following the last dose of blinded study drug

          -  User of recreational or illicit drugs or has had a recent history of drug abuse

          -  Routinely consumes &gt;2 alcoholic drinks per day or &gt;14 alcoholic drinks per week, or
             engages in binge drinking

          -  Has donated blood products or has had phlebotomy of &gt;300 mL within 8 weeks of study
             participation, or intends to donate blood products within the projected duration of
             the trial or has received, or is anticipated to receive, blood products within 12
             weeks of study participation or within the projected duration of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Shankar RR, Inzucchi SE, Scarabello V, Gantz I, Kaufman KD, Lai E, Ceesay P, Suryawanshi S, Engel SS. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 Oct;33(10):1853-1860. doi: 10.1080/03007995.2017.1335637. Epub 2017 Jun 23.</citation>
    <PMID>28547998</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <results_first_submitted>January 30, 2017</results_first_submitted>
  <results_first_submitted_qc>January 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2017</results_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
          <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
          <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase A (Weeks 0-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Creatinine or eGFR Discon. Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Need for Excluded Med. Discon. Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase B (Weeks 24-104)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183">1 participant who completed Phase A did not continue to Phase B.</participants>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omarigliptin (Phase A)</title>
          <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo to Omarigliptin (Phase A)</title>
          <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="402"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="8.1"/>
                    <measurement group_id="B2" value="56.8" spread="9.1"/>
                    <measurement group_id="B3" value="57.2" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C (A1C)</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.06" spread="0.87"/>
                    <measurement group_id="B2" value="8.02" spread="0.89"/>
                    <measurement group_id="B3" value="8.04" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour post-meal glucose (2-hr PMG)</title>
          <description>Omarigliptin (Phase A), n=192; Placebo to omarigliptin (Phase A), n=193; Total, n=385</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240.2" spread="60.5"/>
                    <measurement group_id="B2" value="236.0" spread="59.9"/>
                    <measurement group_id="B3" value="238.1" spread="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.8" spread="37.6"/>
                    <measurement group_id="B2" value="168.6" spread="37.2"/>
                    <measurement group_id="B3" value="168.7" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A)</title>
        <description>A1C is measured as a percent. Change from baseline in A1C at Week 24 was analyzed using a constrained longitudinal data analysis (cLDA) method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A)</title>
          <description>A1C is measured as a percent. Change from baseline in A1C at Week 24 was analyzed using a constrained longitudinal data analysis (cLDA) method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
          <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" lower_limit="-0.69" upper_limit="-0.40"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.14" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>Based on a cLDA method with a restriction of the same baseline mean.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least One Adverse Event (Phase A+B)</title>
        <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Presented data exclude data after glycemic rescue.</description>
        <time_frame>Up to 107 weeks</time_frame>
        <population>All participants as treated population included all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Adverse Event (Phase A+B)</title>
          <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Presented data exclude data after glycemic rescue.</description>
          <population>All participants as treated population included all participants who received at least one dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7"/>
                    <measurement group_id="O2" value="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in %</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>9.8</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method. The 95% CI was computed only for those endpoints with at least 4 participants having events in 1 or more treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A+B)</title>
        <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Presented data exclude data after glycemic rescue.</description>
        <time_frame>Up to 104 weeks</time_frame>
        <population>All participants as treated population included all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A+B)</title>
          <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Presented data exclude data after glycemic rescue.</description>
          <population>All participants as treated population included all participants who received at least one dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in %</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method. The 95% CI was computed only for those endpoints with at least 4 participants having events in 1 or more treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B)</title>
        <description>The following laboratory parameters were included: blood chemistry, hematology, electrocardiograms, lipids, body weight, and vital signs.</description>
        <time_frame>Up to 104 weeks</time_frame>
        <population>All participants as treated population included all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B)</title>
          <description>The following laboratory parameters were included: blood chemistry, hematology, electrocardiograms, lipids, body weight, and vital signs.</description>
          <population>All participants as treated population included all participants who received at least one dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9"/>
                    <measurement group_id="O2" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in %</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24 (Phase A)</title>
        <description>Change from baseline in 2-hour PMG at Week 24 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24 (Phase A)</title>
          <description>Change from baseline in 2-hour PMG at Week 24 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
          <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" lower_limit="-34.8" upper_limit="-18.7"/>
                    <measurement group_id="O2" value="-12.2" lower_limit="-20.7" upper_limit="-3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>cLDA</method>
            <method_desc>Based on a cLDA method with a restriction of the same baseline mean.</method_desc>
            <param_type>Difference in %</param_type>
            <param_value>-14.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.6</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A)</title>
        <description>Change from baseline in FPG at Week 24 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A)</title>
          <description>Change from baseline in FPG at Week 24 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
          <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" lower_limit="-16.0" upper_limit="-5.5"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-6.6" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>cLDA</method>
            <method_desc>Based on a cLDA method with a restriction of the same baseline mean.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.7</ci_lower_limit>
            <ci_upper_limit>-2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Week 104 (Phase A+B)</title>
        <description>A1C is measured as a percent. Change from baseline in A1C at Week 104 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
        <time_frame>Baseline and Week 104</time_frame>
        <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 104 (Phase A+B)</title>
          <description>A1C is measured as a percent. Change from baseline in A1C at Week 104 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
          <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" lower_limit="-0.59" upper_limit="-0.25"/>
                    <measurement group_id="O2" value="-0.51" lower_limit="-0.68" upper_limit="-0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 104 (Phase A+B)</title>
        <description>Change from baseline in FPG at Week 104 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
        <time_frame>Baseline and Week 104</time_frame>
        <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 104 (Phase A+B)</title>
          <description>Change from baseline in FPG at Week 104 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment.</description>
          <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" lower_limit="-14.4" upper_limit="-1.3"/>
                    <measurement group_id="O2" value="-18.2" lower_limit="-24.7" upper_limit="-11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Attaining A1C Glycemic Goals of &lt;7.0% After 24 Weeks of Treatment (Phase A)</title>
        <description>Percentage of participants attaining A1C glycemic goals of &lt;7.0% (53 mmol/mol) after 24 weeks of treatment estimated using standard multiple imputation techniques.</description>
        <time_frame>24 weeks</time_frame>
        <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Attaining A1C Glycemic Goals of &lt;7.0% After 24 Weeks of Treatment (Phase A)</title>
          <description>Percentage of participants attaining A1C glycemic goals of &lt;7.0% (53 mmol/mol) after 24 weeks of treatment estimated using standard multiple imputation techniques.</description>
          <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0" lower_limit="31.3" upper_limit="45.1"/>
                    <measurement group_id="O2" value="18.8" lower_limit="13.9" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Between-group rate difference (%)</param_type>
            <param_value>19.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.1</ci_lower_limit>
            <ci_upper_limit>28.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Attaining A1C Glycemic Goals of &lt;6.5% After 24 Weeks of Treatment (Phase A)</title>
        <description>Percentage of participants attaining A1C glycemic goals of &lt;6.5% (48 mmol/mol) after 24 weeks of treatment estimated using standard multiple imputation techniques.</description>
        <time_frame>24 weeks</time_frame>
        <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Attaining A1C Glycemic Goals of &lt;6.5% After 24 Weeks of Treatment (Phase A)</title>
          <description>Percentage of participants attaining A1C glycemic goals of &lt;6.5% (48 mmol/mol) after 24 weeks of treatment estimated using standard multiple imputation techniques.</description>
          <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="6.8" upper_limit="16.2"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.6" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.164</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Between-group rate difference (%)</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Attaining A1C Glycemic Goals of &lt;7% After 104 Weeks of Treatment (Phase A+B)</title>
        <description>Percentage of participants attaining A1C glycemic goals of &lt;7.0% (53 mmol/mol) after 104 weeks of treatment estimated using standard multiple imputation techniques.</description>
        <time_frame>104 weeks</time_frame>
        <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Attaining A1C Glycemic Goals of &lt;7% After 104 Weeks of Treatment (Phase A+B)</title>
          <description>Percentage of participants attaining A1C glycemic goals of &lt;7.0% (53 mmol/mol) after 104 weeks of treatment estimated using standard multiple imputation techniques.</description>
          <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>Percentage of participants</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" lower_limit="25.7" upper_limit="39.5"/>
                    <measurement group_id="O2" value="39.0" lower_limit="31.7" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Attaining A1C Glycemic Goals of &lt;6.5% After 104 Weeks of Treatment (Phase A+B)</title>
        <description>Percentage of participants attaining A1C glycemic goals of &lt;6.5% (48 mmol/mol) after 104 weeks of treatment estimated using standard multiple imputation techniques.</description>
        <time_frame>104 weeks</time_frame>
        <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Attaining A1C Glycemic Goals of &lt;6.5% After 104 Weeks of Treatment (Phase A+B)</title>
          <description>Percentage of participants attaining A1C glycemic goals of &lt;6.5% (48 mmol/mol) after 104 weeks of treatment estimated using standard multiple imputation techniques.</description>
          <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>Percentage of participants</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="9.4" upper_limit="19.6"/>
                    <measurement group_id="O2" value="17.9" lower_limit="12.5" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PMG Total Area Under the Plasma Concentration Time Curve (AUC) at Week 24 (Phase A)</title>
        <description>Change from baseline in PMG total AUC at Week 24 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment. Plasma glucose levels were measured before the meal (0 minutes), and at 60 and 120 minutes after the meal.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PMG Total Area Under the Plasma Concentration Time Curve (AUC) at Week 24 (Phase A)</title>
          <description>Change from baseline in PMG total AUC at Week 24 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment. Plasma glucose levels were measured before the meal (0 minutes), and at 60 and 120 minutes after the meal.</description>
          <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>mg*h/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.4" lower_limit="-58.7" upper_limit="-34.1"/>
                    <measurement group_id="O2" value="-18.6" lower_limit="-31.5" upper_limit="-5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>cLDA</method>
            <method_desc>Based on a cLDA method with a restriction of the same baseline mean.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-27.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.8</ci_lower_limit>
            <ci_upper_limit>-10.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at Week 24 (Phase A)</title>
        <description>Change from baseline in fasting insulin at Week 24 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at Week 24 (Phase A)</title>
          <description>Change from baseline in fasting insulin at Week 24 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment.</description>
          <population>Full analysis set population included all randomized participants who received at least 1 dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>micro International Unit (μIU)/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="-0.6" upper_limit="4.2"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-4.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>cLDA</method>
            <method_desc>Based on a cLDA method with a restriction of the same baseline mean.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>6.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at Week 104 (Phase A+B)</title>
        <description>Change from baseline in fasting insulin at Week 104 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment.</description>
        <time_frame>Baseline and Week 104</time_frame>
        <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at Week 104 (Phase A+B)</title>
          <description>Change from baseline in fasting insulin at Week 104 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment.</description>
          <population>Full analysis set population included all randomized participants who received at least one dose of study medication and had a baseline measurement or a post-randomization measurement.</population>
          <units>μIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-1.9" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1.8" lower_limit="-1.2" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 24 Weeks (Phase A)</title>
        <description>Participants who did not meet progressively stricter glycemic criteria in Phase A had rescue initiated with open-label glimepiride.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All participants randomized population.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 24 Weeks (Phase A)</title>
          <description>Participants who did not meet progressively stricter glycemic criteria in Phase A had rescue initiated with open-label glimepiride.</description>
          <population>All participants randomized population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="5.3" upper_limit="13.6"/>
                    <measurement group_id="O2" value="9.7" lower_limit="6.2" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.654</p_value>
            <method>Log Rank</method>
            <param_type>Kaplan-Meier difference %</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 104 Weeks (Phase A+B)</title>
        <description>Participants who did not meet progressively stricter glycemic criteria in Phase A had rescue initiated with open-label glimepiride. If during Phase B participants on open-label glimepiride or blinded glimepiride/glimepiride matching placebo needed rescue after maximum up-titration, then insulin glargine was initiated and the dose of open-label glimepiride or blinded glimepiride/glimepiride-matching placebo was discontinued.</description>
        <time_frame>Up to 104 weeks</time_frame>
        <population>All participants randomized population.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 104 Weeks (Phase A+B)</title>
          <description>Participants who did not meet progressively stricter glycemic criteria in Phase A had rescue initiated with open-label glimepiride. If during Phase B participants on open-label glimepiride or blinded glimepiride/glimepiride matching placebo needed rescue after maximum up-titration, then insulin glargine was initiated and the dose of open-label glimepiride or blinded glimepiride/glimepiride-matching placebo was discontinued.</description>
          <population>All participants randomized population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="14.9" upper_limit="27.1"/>
                    <measurement group_id="O2" value="16.2" lower_limit="11.5" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 24 (Phase A)</title>
        <description>Data presented are a cumulative incidence of participants with glycemic rescue by Week 24.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All participants randomized population.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A)</title>
            <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A)</title>
            <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 24 (Phase A)</title>
          <description>Data presented are a cumulative incidence of participants with glycemic rescue by Week 24.</description>
          <population>All participants randomized population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="5.3" upper_limit="13.6"/>
                    <measurement group_id="O2" value="9.0" lower_limit="6.2" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B)</title>
        <description>Data presented are a cumulative incidence of participants with glycemic rescue by Week 104.</description>
        <time_frame>Up to 104 weeks</time_frame>
        <population>All participants randomized population.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
            <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
            <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B)</title>
          <description>Data presented are a cumulative incidence of participants with glycemic rescue by Week 104.</description>
          <population>All participants randomized population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 107 weeks (treatment period + 21-day follow-up)</time_frame>
      <desc>APaT population consists of all randomized participants who took at least 1 dose of study drug. Serious adverse events (SAEs) include data after glycemic rescue; non-serious adverse events exclude data after glycemic rescue. The AEs reported in the (Phase A) → (Phase B) columns are a total of the AEs (SAEs) that occurred in Phases A and B.</desc>
      <group_list>
        <group group_id="E1">
          <title>Omarigliptin (Phase A)</title>
          <description>Phase A: Omarigliptin 25 mg capsule orally once a week for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo to Omarigliptin (Phase A)</title>
          <description>Phase A: Matching placebo to omarigliptin capsule administered orally once weekly for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Omarigliptin (Phase A) → Omarigliptin (Phase B)</title>
          <description>Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)</title>
          <description>Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1, 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1, 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="201"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="201"/>
                <counts group_id="E4" events="14" subjects_affected="10" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E3" events="43" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E4" events="112" subjects_affected="32" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

